Home Ignyta Announces RXDX-101 Phase I Data Abstract Accepted for Oral...
 

Keywords :   


Ignyta Announces RXDX-101 Phase I Data Abstract Accepted for Oral...

2014-05-08 02:51:22| Logistics - Topix.net

Phase 1 open label, dose escalation study of RXDX-101, an oral pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.

Tags: data abstract accepted phase

Category:Transportation and Logistics

Latest from this category

All news

25.11Eastern North Pacific Tropical Weather Outlook
25.11Atlantic Tropical Weather Outlook
25.11Atlantic Tropical Weather Outlook
25.11Eastern North Pacific Tropical Weather Outlook
25.11Eastern North Pacific Tropical Weather Outlook
25.11Atlantic Tropical Weather Outlook
24.11Atlantic Tropical Weather Outlook
24.11Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
25.111/18CTS-V
25.11
25.111
25.11ARS 10+ EHERO 3
25.11 16MGL HG
25.11
25.11GREENMAX 4470 22600Ace4
25.11
More »